Stroke Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have given written consent to participate, or whose legal representative has done so on their behalf.
• People aged 18 years or older and under 85 years old.
• People who have had a stroke caused by a blockage in a large blood vessel, who underwent a mechanical clot removal procedure as part of their standard care, and who still have a partial blockage remaining in certain brain arteries at the end of that procedure, achieved within three or fewer passes of the clot removal device.
• People where the trial treatment can be started within 9 hours of when they were last known to be well before their stroke symptoms began.
• People who have already had their clot removal procedure and, if applicable, received clot-dissolving medication within 9 hours before the planned start of the trial treatment.
• People who had little to no disability from a previous stroke before this event (confirm with trial site).
• People with a stroke severity score of 6 or higher on a standard medical scale at the start (confirm with trial site).
• People whose brain scan shows limited early damage, meeting a specific threshold score, if their symptoms have been present for less than 8 hours (confirm with trial site).
• If a special type of brain blood-flow scan was done, it should show that the area of severely reduced blood flow is 70 mL or smaller (confirm with trial site).
• People whose brain imaging was completed within 75 minutes of the start of their clot removal procedure.

Who may not be able to join:

• People with a very high stroke severity score (above 25) on admission.
• People who needed a stent placed in a neck artery during their procedure and as a result require a specific two-drug blood-thinning treatment.
• People who are pregnant, breastfeeding, or who test positive for pregnancy at the time of admission.
• People currently taking part in another clinical trial involving an experimental drug or device.
• People with a known allergy or sensitivity to iron.
• People with a known inherited or acquired bleeding disorder or clotting factor deficiency.
• People with known blood clotting problems, an elevated clotting blood test result, or who have taken certain newer blood-thinning medications within 12 hours of symptom onset.
• People with a known low platelet count (below 100,000).
• People with known serious kidney disease, based on specific blood test results or kidney function measurements.
• People who need kidney dialysis, or who cannot safely have an imaging procedure that uses dye injected into blood vessels.
• People who have any bleeding visible on a brain scan.
• People whose symptoms suggest bleeding around the brain, even if scans appear normal.
• People where a tear in the main heart artery is suspected.
• People with a current or recent history of illicit drug use or alcohol misuse.
• People with a history of a severe allergic reaction (more than a skin rash) to contrast dye used in imaging.
• People with dangerously high blood pressure that does not respond to treatment.
• People with a serious or terminal illness where life expectancy is less than 6 months.
• People with a pre-existing brain or psychiatric condition that would make it difficult to assess the effects of the treatment.
• People whose stroke is thought to be caused by blood vessel inflammation or an infection-related clot.
• People with a known allergy or sensitivity to contrast dye that cannot be safely managed beforehand.
• People who take the blood-thinning medication Coumadin (warfarin) where stopping it would put their safety at risk.
• People with a known allergy or reason they cannot take a two-drug antiplatelet treatment.
• People with a known allergy or medical reason to avoid iron or polyethylene glycol-based substances.
• People with a known reason they cannot have an MRI scan, such as having a pacemaker, certain implanted devices, or certain metal clips in the body (confirm with trial site for full list).
• People whose body size or shape prevents the trial's magnet device from being correctly positioned.
• People showing signs of a body-wide infection or sepsis, based on elevated temperature or white blood cell count — though people with a contained or well-treated local infection may still be considered at the researcher's discretion.
• People with a known or suspected heart condition causing certain types of abnormal heart rhythm or blood pressure problems requiring medical treatment.
• People with a known or suspected condition causing excess iron build-up in the body.
• People with known or suspected liver disease, such as hepatitis or cirrhosis.
• People who have received iron replacement therapy or an iron-based MRI contrast agent within the past 30 days.

Important: Always verify eligibility with the trial site directly before applying.